Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 892 across all filing types
Latest filing 2014-04-16 Annual Report
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Annual Report 2013
Annual Report Classification · 100% confidence The document is titled 'årsredovisning 2013' (Annual Report 2013) for the company Sobi. It contains a comprehensive overview of the company's activities, financial performance, management commentary, board information, and audited financial statements (as indicated by the table of contents referencing 'Koncernens räkenskaper', 'Noter', and 'Revisionsberättelse'). This is a full annual report, not an announcement or a summary. FY 2013
2014-04-16 Swedish
Annual Report 2013
Annual Report Classification · 100% confidence The document is explicitly titled 'annual report 2013' and contains comprehensive sections including a CEO statement, key figures, directors' report, corporate governance, and full group financial statements. It covers the company's performance, strategy, and financial results for the 2013 fiscal year, fitting the definition of an Annual Report (10-K). FY 2013
2014-04-16 English
Sobi publishes Annual Report 2013
Report Publication Announcement Classification · 99% confidence The document is titled "Sobi publishes Annual Report 2013". It explicitly states that the company "published its Annual Report for 2013". However, the document itself is very short (2203 characters) and primarily serves as an announcement or press release summarizing the availability of the full report on their website, rather than containing the full, detailed financial statements characteristic of a 10-K or IR filing. According to Rule 2, when a document announces the publication of a report and is short, it should be classified as a Report Publication Announcement (RPA). The content focuses on the theme and highlights of the report, not the detailed financial tables themselves.
2014-04-16 English
Sobis årsredovisning för 2013 publicerad
Report Publication Announcement Classification · 99% confidence The document is a press release titled "Sobis årsredovisning för 2013 publicerad" (Sobi's annual report for 2013 published). It explicitly states that the company published its annual report for 2013 on its website. The document itself is short (2083 characters) and serves to announce the availability of the full report, rather than being the comprehensive report itself. According to Rule 2 (The "MENU VS MEAL" RULE), a short announcement stating that a report has been published points towards a Report Publication Announcement (RPA). While the content relates to an Annual Report (10-K), the document's function here is the announcement of its publication.
2014-04-16 Swedish
Biogen Idec and Sobi announce positive top-line efficacy and safety results from phase-3 paediatric study of investigational therapy Eloctate(TM) (rFVIIIFc) for haemophilia A
Earnings Release Classification · 99% confidence The document is explicitly titled "PRESS RELEASE" and announces "positive top-line efficacy and safety results from phase-3 paediatric study of investigational therapy Eloctate™". This content structure—a brief announcement highlighting key results (efficacy, safety, primary objectives met) followed by background on the study and the drug—is characteristic of an Earnings Release (ER) or a general press release announcing significant corporate/clinical news. Since it focuses purely on clinical trial results and their implication for regulatory submission, it is best classified as an Earnings Release (ER) as it serves as the initial public disclosure of performance-related data, even if not strictly quarterly financial results. It is not a full Annual Report (10-K), an Interim Report (IR), or a formal Investor Presentation (IP). It is a direct announcement of results, not just an announcement *about* a report (RPA). FY 2014
2014-04-10 English
Biogen Idec och Sobi meddelar positiva resultat gällande effekt och säkerhet från Kids A-LONG, bolagens fas-3 studie på barn av läkemedelskandidaten Eloctate(TM) (rFVIIIFc) för hemofili A
Earnings Release Classification · 95% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and announces positive Phase 3 study results (Kids A-LONG) for a drug candidate (Eloctate) developed by Biogen Idec and Sobi. It details clinical outcomes, safety profiles, and the implication for marketing authorization applications (EMA). This type of announcement, which releases key financial/clinical results for a period or event, aligns best with an Earnings Release (ER) or a general announcement. Since it is a press release announcing clinical trial results rather than a formal regulatory filing like a 10-K or a comprehensive quarterly report (IR), and it focuses on key performance indicators (study results), 'ER' (Earnings Release) is the most appropriate fit among the provided options for a major corporate announcement of results, even if the results are clinical rather than purely financial. It is not a transcript (CT), a presentation (IP), or a formal report (AR/IR). Given the context of corporate reporting, ER is used broadly for major result announcements. FY 2014
2014-04-10 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.